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Research over the role of Bruton’s agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development,
differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies.
Down-regulation of BTK activity is an attractive novel strategy for treating patients with B-cell malignancies.
Ibrutinib (PCI-32765), a potent inhibitor of BTK induces impressive responses in B-cell malignancies through
irreversible bond with cysteine-481 in the active site of BTK (TH/SH1 domain) and inhibits BTK phosphorylation
on Tyr223. This review discussed in details the role of BTK in B-cell signaling, molecular interactions between
B cell lymphoma/leukemia cells and their microenvironment. Clinical trials of the novel BTK inhibitor, ibrutinib
(PCI-32765), in B cell malignancies were summarized.Introduction
Bruton’s tyrosine kinase (BTK) is a cytoplasmic tyrosine
kinase, which is essential in B-lymphocyte development,
differentiation, signaling and survival [1]. The BTK gene is
located on X-chromosome at Xq21.33-Xq22. The gene
has 19 exons spanning 37.5 kb genomic DNA. It encodes
a non-receptor tyrosine kinase of the Btk/Tec family. The
Tec family kinases (TFKs) have five members (Btk, Tec,
Itk, Txk, Bmx), forming the second largest family of cyto-
plasmic tyrosine kinases in mammalian cells [2]. BTK is
expressed in almost all hematopoietic cells, except T-cells
and plasma cells. However, its essential functions appear
to be limited to B-cells. BTK is required for B-cell receptor
(BCR) signaling and implicated in the development of
the B-cell malignancies including chronic lymphocytic
leukemia (CLL), mantle cell lymphoma (MCL), follicu-
lar lymphoma (FL), diffuse large B-cell lymphoma
(DLBCL) and acute lymphocytic leukemia (ALL) [3,4].
Several preclinical and clinical studies have been
performed, targeting BTK in B-cell malignancies.
Ibrutinib/PCI-32765, a novel potent inhibitor of BTK
induces impressive responses in B-cell malignancies and
has been approved for therapy of refractory mantle cell
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BCR is critical for normal B-cell development and is also
associated in the development of the most common B-
cell malignancies [5-7]. BCR serves as an antigen recep-
tor and regulates multiple cellular processes, including
proliferation, differentiation, apoptosis, and cell migra-
tion [2,8]. The BCR consists of a transmembrane im-
munoglobulin (Ig) receptor associated with the Ig-alpha
(CD79a) and Ig-beta (CD79b) heterodimers [7,9-11].
Once the antigen binds to the receptor, the tyrosine ki-
nases LYN and SYK initiate a signaling cascade that in-
volves downstream kinases, adapter molecules, and
generation of second messengers [9] (Figure 1). BTK is
one of the signaling molecules that is essential in the
BCR pathway. BTK comprises of several domains from
the N-terminus: pleckstrin homology (PH), Tec hom-
ology (TH), SH2, SH3, and kinase (SH1) domains [1].
BTK requires Zn2+ for optimal activity and stability.
Binding and coordination of BTK to the Zn2+ ion is me-
diated by a highly conserved zinc finger motif located in
the TH domain. Mutations affecting Zn2+ binding lead
to the generation of extremely unstable protein [12,13].
Additional signaling molecules in the BCR signaling
pathway include mammalian target of rapamycin (mTOR),
SYK, LYN, phosphatidylinositol 3- kinase (PI3K) [14,15],
the adaptor protein GrB2. The activation of BTK and
PI3 kinase prompts calcium release and activation of
mTOR, protein kinase C-beta, AKT kinase, and mitogen-
activated protein kinase ERK. These events then result in
cell proliferation and survival of B-cells, which is mediatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 A schematic representation of BCR/BTK signaling pathway. The BCR consists of a transmembrane immunoglobulin (Ig) receptor
associated with the Ig-alpha (CD79a) and Ig-beta (CD79b) heterodimers. The activation of BTK and PI3 kinase after antigen binding to BCR
prompts calcium release, which leads to activation of the signaling cascade. BCR: B cell receptor; BTK: Bruton’s tyrosine kinase.
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factor-kB (NFkB). Upon activation of BTK, PI3K is
then activated, which stimulates the production of
phosphatidylinositol-3, 4, 5 (PIP3) [14,15]. Once an ad-
equate amount of PIP3 is produced, BTK is mobilized
to the plasma membrane. Phosphorylation of the BTK
at the Y551 site is done by the Src family kinases, espe-
cially LYN and FYN. The phosphorylated BTK activates
phospholipase C2, leading to downstream activation of
protein kinases, and finally activation of transcription
factor NFkB. The stimulation of NFkB pathway leads to
inhibition of apoptosis (Figure 1). This series of events
has been associated with the proliferation and survival
of B-cell malignancies [16,17]. BTK was found to be
significantly overexpressed in CLL compared with nor-
mal B-cells. Although BTK is not always constitutively
active in CLL cells, BCR or CD40 signaling is accom-
panied by effective activation of this pathway.
Preclinical studies
Ibrutinib is an orally active irreversible BTK inhibitor
through bonding with cysteine-481 in the active site of
BTK (TH/SH1 domain). It inhibits BTK phosphorylation
on Tyr223 and has an IC50 of 0.5 nM for more than 24
hours [18]. In an in vitro study, Herman et al. demon-
strated dose- and time-dependent cytotoxicity in CLL
through caspase-3 dependent apoptotic pathway [19].
Efficacy of ibrutinib was also investigated using a canine
model of B-cell lymphoma. There was a 70% reduction
in tumor burden. After testing for BTK occupancy, it
was determined that a single dose of 2.5 to 20 mg/kgwas sufficient to fully occupy BTK [18]. Furthermore,
ibrutinib can affect the CLL microenvironment by inhi-
biting CD40, BAFF, Toll-like receptor and cytokine sig-
naling [20]. The above preclinical findings have led to
further clinical trials [21].
Clinical studies
Chronic lymphocytic leukemia (CLL) A phase 1 dose
escalation study of ibrutinib as a single agent enrolled 56 pa-
tients with relapsed/refractory B-cell malignancies, including
non-Hodgkin’s lymphoma, CLL, and Waldenstrom’s macro-
globulinemia [22,23]. In this study, ibrutinib was well
tolerated with substantial activity across B-cell histolo-
gies. Fifty-six patients were treated over seven cohorts.
Ibrutinib was administered in 1.25, 2.5, 5.0, 8.3, 12.5 and
17.5 mg/kg/day dose orally once per day for 28 days
followed by a 7-day rest period to determine maximum
tolerated dose (MTD). Pharmacokinetic studies showed
that ibrutinib had a mean peak plasma concentration ob-
served at 1–2 hours after administration. Most adverse
events were grade 1 and 2 (including neutropenia and
thrombocytopenia) and self-limited. Dose limiting events
were not observed, even with prolonged dosing. Full occu-
pancy of the BTK active site occurred at 2.5 mg/kg/day,
and dose escalation continued to 12.5 mg/kg/day without
reaching MTD. The dose of 420 mg daily was chosen for
further studies. Objective response rate (RR) in 50 evalu-
able patients was 60%, including complete response (CR)
of 16% and median PFS in all patients was 13.6 months.
With the promising results of phase 1 study in CLL, a
phase 1b/II study was done to evaluate the efficacy,
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total of 85 patients with relapsed/refractory CLL/SLL re-
ceived ibrutinib, the first-in-class, oral covalent inhibitor
of BTK; Among these 85 patients, 51 received 420 mg
and 34 received 840 mg. The overall RR was the same
for both groups (71%), and an additional 20% and 15%
of patients in the respective group had a partial response
with lymphocytosis (PR-L). The response was independ-
ent of clinical and genomic risk factors present before
treatment, including advanced-stage disease, the number
of previous therapies and 17p13.1 deletion. After 26
months of follow-up, the estimated PFS and OS rates
were 75% and 83% respectively. Lymphocytosis was
found to be treatment related and was not a sign of dis-
ease progression. It was thought to be due to lympho-
cyte mobilization by ibrutinib from bone marrow, lymph
nodes, and spleen where stromal elements promote
leukemic-cell proliferation, drug resistance, and survival.
Another interesting finding from this study was that pa-
tients with IgVH unmutated (hence higher risk) had
earlier resolution of lymphocytosis and higher response
rate (P = 0.02). This was possibly due to the fact that
these B cells tend to have higher BCR signaling and
therefore more dependence on this pathway [25].
An interim update reported phase Ib/II data from 116
patients who were grouped into three cohorts [26]. First
cohort included 31 treatment -naïve patients aged ≥ 65
in which 26 patients received 420 mg/day of Ibrutinib
whereas 5 received 840 mg daily. Second cohort com-
prised relapsed/refractory CLL patients (n = 61), out of
which 27 patients received 420 mg of Ibrutinib per day
and 34 received 840 mg/day. Third group with high-risk
relapsed/refractory (defined as relapse within two years
following treatment and/or presence of 17p deletion) re-
ceived ibrutinib 420 mg (n = 24). For the treatment-
naïve CLL patients >65 years old, their median age was
71 years old (age 65–84) and the median follow-up dura-
tions for the whole group was 16.6 months (range 1.4-
23.2). Unmutated IgVH, 11q deletion, and 17p deletion
were found in 55%, 3%, and 7% of patients in this co-
hort. The overall RR by International Workshop on CLL
criteria was 71% (10% CR and 61% PR). Among these,
PR-L was 10%. This PR-L, defined as 50% reduction in
lymphadenopathy with residual lymphocytosis, is not
considered as clinical progression but rather as a form
of response called compartmental shift where the drug
induces mobilization of leukemic B cells from the bone
marrow and spleen into the blood. Overtime, many of
the patients had more than 50% decrease in absolute
lymphocyte count compared with baseline [26-29]. For
the relapsed/refractory CLL cohort, the median age was
64 years old (range 40–81) and the number of prior
treatments were four for the whole cohort. There were
unmutated IgVH (86%), 17p deletion (37%) and 11qdeletion (40%) documented. Median follow up was
17.5 months for patients who received 420 mg and
10.3 months for those who received 840 mg. The overall
RR was 67% (CR = 3% and PR 64%). Lastly, for high-risk
CLL, all 24 patients received 420 mg of ibrutinib.
Median age was 68 years old (range 37–82) with a me-
dian of four prior treatments. The documented unmu-
tated IgVH, 17p deletion, and 11q deletion were 83%,
30% and 35%, respectively. The median follow-up was
10.3 months (range 1.1-11.5) and the overall response
was 50%, all partial remissions, with 29% achieving PR-L
(Table 1). Four percent of patients had progressed while
on treatment. The adverse effects reported were grade 1
to 2 including joint pain, nausea, rash, infection, upper re-
spiratory infection, diarrhea and fatigue. Rare hematologic
side effects were also observed including neutropenia and
thrombocytopenia [26-29]. Lymphocytosis was again
found to resolve faster and occur more frequently in CLL
patients with unmuted IgVH. The results of these studies
also show that although the response rates were high, the
CR rate with ibrutinib remained low; therefore, the activity
of this drug needs to be evaluated in patients who have re-
ceived less treatment.
Single agent ibrutinib is being compared with ofatumu-
mab for R/R CLL (RESONATE trial) [30]. RESONATE-2
will investigate single agent ibrutinib versus chlorambucil
as frontline therapy for newly diagnosed elderly patients
with CLL [31].
Mantle cell lymphoma (MCL) MCL is characterized by
the overexpression of cyclin D1 due to the translocation
t (11:14) (q13; q32). Although there are promising treat-
ment modalities, a great majority of patients with MCL
remain incurable [32]. Cinar et al. demonstrated a mod-
erate to strong BTK expression in all MCL cases (n = 19)
compared to benign lymphoid tissues. Treatment of
MCL cell lines (Mino or Jeko-1) with ibrutinib resulted
in decreased phospho-BTK-Tyr223 expression. Also,
ibrutinib inhibited the viability of both Mino and JeKo-1
cells in concentration- and time-dependent manners.
Ibrutinib also induced concentration-dependent apoptosis
in both cell lines and decreased the levels of anti-
apoptotic Bcl-2, Bcl-xL, and Mcl-1 protein. These findings
suggest that BTK signaling plays an integral role in MCL
cell survival and targeting of BTK is an encouraging thera-
peutic modality for this type of disease [32,33]. In a phase
1 study of ibrutinib, there is an antitumor activity in sev-
eral types of NHL including mantle cell lymphoma. A
Phase 2 study was performed where ibrutinib was investi-
gated at a daily dose of 560 mg in 111 patients with re-
lapsed/refractory mantle-cell lymphoma [34]. Patients
were divided into two groups: 1) those who received at
least 2 cycles of bortezomib therapy; 2) those that had re-
ceived less than 2 complete cycles of bortezomib or had
Table 1 Ibrutinib in clinical trials for chronic lymphoid leukemia
Studies Phase Ib/II for
CLL/SLL















[N=85] [24] [N=40] [40] [N=40] [41]
ORR 71% 71% (CR=10%, PR=61%) 67 % (CR=3%, PR=64%) 50% (PR=50%, CR=0%) 85% 100%
ORR = overall response rate; CR = complete remission; PR = partial remission.
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the overall response rate (ORR). Secondary end points
were duration of response, PFS, OS and safety. The me-
dian age was 68 years old, and 86% of patients had
intermediate-risk or high-risk mantle-cell lymphoma ac-
cording to clinical prognostic factors. A response rate of
68% (75 patients) was observed, with a complete remis-
sion rate of 21% and a partial response rate of 47%; prior
treatment with bortezomib had no effect on the response
rate. Median follow-up was 15.3 months and the esti-
mated median response duration was 17.5 months. The
median OS was not reached, the estimated rate of OS was
58% at 18 months. The most common treatment-related
adverse effects were mild to moderate diarrhea, nausea
and fatigue. Grade 3 or higher hematologic events in-
cluded neutropenia (16%), thrombocytopenia (11%) and
anemia (10%). The study shows that ibrutinib is a durable
single-agent effective in relapsed/refractory MCL. Ibruti-
nib was approved by FDA for relapsed/refractory MCL
who at least received one prior therapy. However, the
complete response rate is lower than that associated with
combination regimens, and it is not yet known whether
the addition of ibrutinib can improve the molecular re-
sponse rate.
Diffuse large B cell lymphoma and multiple myeloma
There are early studies of ibrutinib in DLBCL and mul-
tiple myeloma. These studies have shown that ibrutinib
has cytotoxic effects on these cells and warrants further
research. Dasmahapatra et al. examined the interaction
of ibrutinib and the proteasome inhibitor (bortezomib)
in DLBCL and mantle cell lymphoma cells, including
those highly resistant to bortezomib. Co-administration
of ibrutinib and bortezomib synergistically increased
mitochondrial injury and apoptosis in germinal center or
activated B-cell like DLBCL and MCL cells. These events
were accompanied by marked AKT and NFkB inactiva-
tion, down-regulation of Mcl-1, Bcl-xL and XIAP which
enhanced DNA damage and endoplasmic reticulum stress.
The same interactions were seen in highly bortezomib-
resistant DLBCL and MCL cells and in primary DLBCL
cells [35]. On the other hand, Rushworth et al. reported
that ibrutinib is cytotoxic to malignant plasma cells from
patients with multiple myeloma and the treatment withibrutinib significantly augments the cytotoxic activity of
bortezomib and lenalidomide chemotherapies. It was de-
scribed that the cytotoxicity of ibrutinib in multiple mye-
loma is mediated through an inhibitory effect on the
NFkB pathway. In addition, ibrutinib blocks the phosphor-
ylation of serine-536 of the p65 subunit of NFkB, prevent-
ing its nuclear translocation, leading to down regulation of
anti-apoptotic proteins Bcl-xL, FLIP and survivin, culmin-
ating in caspase-mediated apoptosis within the malignant
plasma cells [36,37].
It has been shown that activated B cell (ABC) but not
germinal center B cell (GCB) subtypes of DLBCL cell
lines are driven by "chronic active" B cell receptor (BCR)
signaling [5,38]. BCR subunit CD79B mutations occur in
21% of ABC but only 5% of GCB DLBCL tumors. In a
phase 2 study patients with relapsed/refractory DLBCL
received ibrutinib 560 mg daily [39]. Seventy subjects
were enrolled; median age was 63 yrs (28–92); median
prior systemic therapies 3 (1–7); 23% had prior stem cell
transplant. Ibrutinib was well tolerated. In the ABC sub-
type (N = 29), ORR was 40% (10/25), CR 8% (2/25) and
PR 32% (8/25). The median PFS was 5.5 months in
ABC responders. PR was observed in only one with the
GCB subtype (N = 20) and none in unclassifiable cases
(N = 16). Therefore preferential response favored ABC
subtype of DLBCL (p = 0.0126), but ibrutinib sensitivity
did not require a BCR mutation. These results suggest
that future clinical trials of ibrutinib in DLBCL should
aim for patients with ABC subtype of DLBCL.
Ibrutinib in combination therapy
The encouraging results of ibrutinib in treatment naïve
and relapse/refractory(R/R) CLL led the investigators to
explore combination therapy to determine. Ibrutinib has
been studied in combination with rituximab in R/R CLL
(n = 40). This combination has an ORR of 85% [40]
(Table 1). This was a phase 2 single-center study of 40
high-risk patients at the time of analysis. Patients were
treated with ibrutinib 420 mg daily and weekly rituximab
(375 mg/m2) for weeks 1–4 (cycle 1), then daily ibruti-
nib plus monthly rituximab until cycle 6. This was then
followed by ibrutinib daily. The median age was 65
(range 35–82) with a median of 2 prior therapies.
Among these, 19 patients had del17p or TP53 mutation
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median follow up of 4 months, 17 out of 20 patients eva-
luable for efficacy achieved a partial remission (PR) for an
ORR of 85%, and three achieved a PR with persistent lym-
phocytosis. In this combination trial, the re-distribution
lymphocytosis was noted to peak earlier and the duration
was shorter than with single-agent ibrutinib. Treatment was
well tolerated and induced very high early response rates.
Ofatumumab was also studied with ibrutinib in re-
lapsed/refractory (R/R) CLL (n = 40) with an ORR of
100% [41]. In this report, 27 patients with CLL/SLL fol-
lowing 2 prior therapies received 420 mg daily, in 28-
day cycles. Ofatumumab (O) is added at a dose of
300 mg on day 1 of cycle 2, followed by 2000 mg on day
8, 15, and 22 of cycle 2, Day 1, 8, 15, and 22 of cycle 3,
and on day 1 of cycles 5–8. This combination had rapid
onset of response, low relapse rate and favorable safety
profile.
Ibrutinib was combined with bendamustine (B) and ri-
tuximab (R) in a phase I study in patients with relapsed/
refractory NHL (FL, MZL, MCL, transformed NHL, and
DLBCL) [42]. Treatment consisted of standard R
375 mg/m2 day 1, B 90 mg/m2 days 1 and 2, with escal-
ating doses of ibrutinib (280 mg or 560 mg) every 28
days for 6 cycles. Ibrutinib was continued after cycle 6 in
responding patients. Pegfilgrastim was used for patients
with severe neutropenia. Eleven patients were enrolled,
with a median age of 72 (range 45–84) and a median of
3 prior therapies (range 0–10). Nine patients completed
two or more cycles of therapy (median 3, range 1–6), of
whom 6 received 280 mg and 3 treated with 560 mg of
ibrutinib. No DLTs were observed. Severe lymphopenia
(64%) was the most common adverse events. Three pa-
tients required dose reductions from 280 mg ibrutinib to
140 mg. Bendamustine dose was reduced to 60 mg/m2
in 1 patient for grade 3 thrombocytopenia. ORR was
38% in 8 evaluable patients. There are phase III clinical
trials currently ongoing that test the efficacy of BR +/−
ibrutinib in R/R CLL patients. There is also a phase 3
study of BR +/− ibrutinib as front-line therapy for MCL
(the SHINE trial, MCL3002).
Phase 1b trial assessing the feasibility of incorporating
ibrutinib with R-CHOP was updated at 2013 ASCO [43].
In this study, ibrutinib was given as 280, 420, or 560 mg
daily in combination with standard R-CHOP. 17 patients
were enrolled. At 560 mg dosage, 1 patient had grade 2
gastritis. The phase 2 dose was established at 560 mg
daily. The most common adverse event was neutropenia
(77%). The response rate was 100% at the time of ana-
lysis in 10 patients (7 CR and 3 PR).
Conclusion and future directions
Novel agents are being studied for CLL and lymphoid
malignancies [14,32,44-49]. Ibrutinib as a single agenthas brought encouraging results for the targeted therapy
of B-cell lymphoproliferative malignancies. Ibrutinib tar-
gets B-cell receptor signaling in CLL/MCL cells. Lym-
phocytosis with ibrutinib therapy is a remarkable clinical
phenomenon, and can stay for a prolonged period of
time. Additional novel BTK inhibitors (GDC-0834, CC-
292, ONO-4059, CNX-774, LFM-A13 and HM-71224)
are currently under active investigation [1]. Further re-
search is warranted to assess long-term effects of pro-
longed use, such as hypogammaglobulinemia, unusual
side effects and opportunistic infection [50]. It is also in-
teresting to evaluate the use of BTK inhibitors in peri-
transplantation as well as possible maintenance therapy
on high-risk patients. Low CR rate from ibrutinib single
agent therapy remains a concern. Ibrutinib appears to
have activity in myeloma [36,37,51]. Ibrutinib in combin-
ation regimens is an intense focus of research in an at-
tempt to improve the response quality.
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